Structural basis for inhibition of protein tyrosine phosphatases by Keggin compounds phosphomolybdate and phosphotungstate by 김종선 & 박전한
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 34, No. 3, 211-223, July 2002Structural basis for inhibition of protein tyrosine phosphatases by 
Keggin compounds phosphomolybdate and phosphotungstate
Yong-Seok Heo1, Jung Min Ryu2, 
Sang Myun Park2, Jeon Han Park2,
Hyun-Chul Lee3, Kwang Yeon Hwang1, 4,
Jongsun Kim2, 4
1 CrystalGenomics, Inc., Taejon, Korea
2 Department of Microbiology and Brain Korea 21 Project of Medical
Sciences, Yonsei University College of Medicine, Seoul, Korea
3 Department of Internal Medicine, Yonsei University College of
Medicine
4 Corresponding author: Tel, +82-2-361-5277;
Fax, +82-2-392-7088; E-mail: jkim63@yumc.yonsei.ac.kr
Accepted 4 July 2002
Abbreviations: PTP, protein tyrosine phosphatase; PTK, protein
tyrosine kinase; SHP-1, SH2 domain containing protein tyrosine
phosphatase-1; pNPP, p-nitrophenyl phosphate; PM, phosphomo-
lybdate; PT, phosphotungstate; LAR, leukocyte common antigen-
related protein tyrosine phosphatase; PP1, human protein phos-
phatase 1; CIP, alkaline phosphatase of calf intestine; OBA, 2-
(Oxalylamino)benzoic acid; bpV, Bis-peroxo(bipyridine)oxovana-
date.
Abstract
Protein-tyrosine phosphatases (PTPs) constitute a
family of receptor-like, and cytoplasmic enzymes,
which catalyze the dephosphorylation of phosphoty-
rosine residues in a variety of receptors and signal-
ing molecules. Together with protein tyrosine
kinases (PTKs), PTPs are critically involved in regu-
lating many cellular signaling processes. In this
study, diverse compounds were screened for PTP
inhibition and selectively screened for inhibitors
with the end product inhibition properties. Among
phosphate analogues and their derivatives for PTP
inhibition, Keggin compounds phosphomolybdate
(PM) and phosphotungstate (PT) strongly inhibited
both PTP-1B and SHP-1, with Ki values of 0.06-1.2
µM in the presence of EDTA. Unlike the vanadium
compounds, inhibition potencies of PM and PT were
not significantly affected by EDTA. PM and PT were
potent, competitive inhibitors for PTPs, but rela-
tively poor inhibitors of Ser/Thr phosphatase. Inter-
estingly, PM and PT did not inhibit alkaline
phosphatase at all. The crystal structure of PTP-1B
in complex with PM, at 2.0 Å resolution, reveals that
MoO3, derived from PM by hydrolysis, binds at the
active site. The molybdenium atom of the inhibitor is
coordinated with six ligands: three oxo-ligands, two
apical water molecules and a S atom of the catalytic
cysteine residue. In support of the crystallographic
finding, we observed that molybdenium oxides
(MoO3, MoO2, and MoO2Cl2) inhibited PTP-1B with
IC50 in the range 5-15 µM.
Keywords: Protein-tyrosine-phosphatase, molybde-
num, tungsten compounds, enzyme inhibitors, crystal-
lography
Introduction
Reversible protein tyrosine phosphorylations, controlled
by competing activities between protein-tyrosine kinases
(PTKs) (Zhang, 1998) and protein-tyrosine phosphatases
(PTPs), are critically involved in regulating many cellular
signaling processes, where the propagation and ter-
mination of signaling events are determined by the level
of protein tyrosine phosphorylation (Fischer et al., 1991,
Hunter, 1995, Neel and Tonks, 1997, Zhang, 1998).
Classical PTP family members can be classified into two
groups, receptor-like PTPs, which are represented by
LAR (leukocyte common antigen-related protein tyrosine
phosphatase) and PTPα, and cytosolic PTPs, which are
represented by PTP-1B and SHP-1 (Denu and Dixon,
1998, Hooft van Huijsduijnen, 1998). PTPs have been
considered to have extremely low substrate specificity,
since they are known to dephosphorylate multiple target
molecules unrelated to one another, when assayed in
vitro, or by overexpression in cells (Zhang and Dixon,
1994, Tonks and Neel, 1996). However, recently
reported knockout mice, deficient of particular PTPs, all
appear to exhibit unique phenotypes, suggesting each
PTP has a specific, or very limited target molecule(s) in
vivo (Kishihara et al., 1993, Shultz et al., 1993,  Tsui et
al., 1993, Saxton et al., 1997, Schaapveld et al., 1997,
You-Ten et al., 1997, Cote et al., 1998, Ren et al., 1998,
Elchebly et al., 1999a, Elchebly et al., 1999b).
Therefore, highly selective PTP inhibitors could be used
as therapeutic agents for diseases, as well as for the
elucidation of biological functions of enzymes.
Based on the potential therapeutic and biological
usefulness of selective PTP inhibitors, significant
progress in developing such agents is being made
(Burke and Zhang, 1998, Kennedy and Ramachandran,
2000). For example, vanadate and its derivatives such
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characterized PTP inhibitors, but appear to be non-
specific among the PTP family members (Swarup et al.,
1982, Posner et al., 1994, Huyer et al., 1997,). PTP
substrate analogues, in which the cleavable O-P linkage
has been replaced by PTP-resistant chemical linkage,
such as sulfotyrosine, thiophosphotyrosine, O, O-dicar
boxymethyltyrosine, phosphonomethyl phenylalanine, and
4-[difluoro(phosphono)methyl]phenylalanine, have been
shown as potent inhibitors of PTPs (Burke et al., 1994,
Liotta et al., 1994, Zhang et al., 1994, Kole et al., 1995,
Burke et al., 1996, Huyer et al., 1998, Desmarais et al.,
1999). Particularly, phosphonate compounds incorporated
in peptides are being developed as relatively selective
inhibitors of PTPs (Chen et al., 1995, Taing et al., 1999).
Recently, simple organic molecules such as 2-(ox-
alylamino)benzoic acid (OBA) and its derivatives
(Andersen et al., 2000, Iversen et al., 2000), and ben-
zofuran and benzothiophen biphenyls compounds (Ma-
lamas et al., 2000) have turned out to be potent inhibitors.
In this study, we embarked on identifying general,
potent, reversible PTP inhibitors that could be used as
lead compounds for developing selective PTP
inhibitors, focusing on the end product inhibition
properties of PTPs. We screened various derivatives
of phosphate, and phosphate analogues, for the PTP
inhibition, and found that Keggin compounds
phosphomolybdate (PM) and phosphotungstate (PT)
strongly inhibited the PTPs. 
Materials and Methods
Materials
An E. coli expression vector, pRSETA, was purchased
from Invitrogen (Carlsbad, CA), and an E. coli strain for
the protein expression, BL21 (DE3) pLysS, was from
Stratagene (La Jolla, CA). Bradford solution, for protein
assays, was purchased from Bio-Rad (Hercules, CA).
Centriprep and Centricon were purchased from Amicon
(Berverly, MA), and DEAE sepharose CL-6B was from
Amersham Pharmacia (Uppsala, Sweden). p-Nitophenyl
phosphate (pNPP), sodium orthovanadate, sodium mo-
lybdate, sodium tungstate, PM, PT vanadyl sulfate,
thiophosphate, glutathion (GSH), leupeptin, dithiothreitol
and isopropyl β-D-l-thiogalactopyranoside (IPTG) were
purchased from Sigma (St. Louis, MO). Bis-
peroxo(bipyridine)oxovanadate (bpV), a peroxovanadium
compound (Posner et al., 1994) was purchased from Alexi
Biochemicals (San Diego, CA). The catalytic domains of
LAR, PP1 (the γ form of human protein phosphatase 1)
and CIP (alkaline phosphatase of calf intestines) were
purchased from New England Biolab  (Berverly, MA).
PCR cloning and expression of the catalytic
domains of PTP-1B and SHP-1
Total RNA was isolated from peripheral blood
mononuclear cells (PBMCs) of a heathy volunteer, and
the first strand cDNA of the total RNA was synthesized
as described previously (Kim et al., 1997). The protein
coding region of the catalytic domain of PTP-1B
(Chernoff et al., 1990) was amplified by PCR using 10 µl
of the cDNA and Taq polymerase with the 5´-oli-
gonucleotide primer 5´-CGGATCCATATGGAGATGGAA
AAGGAGTTC and the 3´-oligonucleotide primer 5´-
CCGTACGGATCCTTAATTGTGTGGCTCCAGGATTCG,
containing the underlined NdeI and BamHI restriction
sites, respectively. The protein coding region of the
catalytic domain of SHP-1 (Shen et al., 1991) was
amplified similarly with the 5´-oligonucleotide primer 5´-G
GAATTCCATATGGGCTTCTGGGAGGAGTTTGAG
and  the 3´-oligo nucleotide primer 5´-GGGAAGCTT
CTAATAGGTGATGTTCCCGTA, containing the underlined
NdeI and HindIII restriction sites, respectively. The
amplified DNAs were gel purified, digested with
appropriate restriction enzymes, and ligated into an E.
coli expression vector, pRSETA, which had been
previously digested with the restriction enzymes, and
gel purified. The recombinant DNAs were transformed
into the E. coli strain DH5α, and clones containing the
correct insert were identified by restriction digest, and
the inserts confirmed by DNA sequencing.
The plasmids containing the catalytic domain of PTP-1B
and SHP-1 were transformed into the E. coli strain BL21
(DE3) pLysS for protein expression. Three liters of
bacteria, carrying the recombinant plasmids, were grown
from a single colony at 37oC in LB medium containing 100
µg/ml of ampicilin, and induced with 0.5 mM IPTG at
OD600 of 0.8. Four hours after the induction, bacteria were
harvested by centrifugation. 
Purification of the Recombinant PTP-1B and SHP-1 
The recombinant PTP-1B was purified by conventional
column chromatographic techniques. The bacterial pellet
was disrupted by sonication at 4oC in a lysis buffer containing
25 mM Tris-HCl, pH 7.5, 10 mM β-mercaptoethanol, 10 mM
EDTA, 0.002% phenylmethylsulfonyl fluoride and 20 µg/mL
leupeptin. The homogenate was then centrifuged for 10
min at 4oC at 10,000 rev./min. The supernatant containing
the soluble form of PTP-1B was loaded onto a DEAE
Sepharose-CL 6B column, which was pre-equilibrated with
QA buffer (25 mM Tris-HCl, pH 7.5, 2 mM β-mercaptoe-
thanol, 1 mM EDTA). The column was washed with the
QA buffer and the bound proteins were eluted from the
column using a linear gradient from 0 to 0.5 M NaCl in 200
mL of QA buffer. The eluted PTP-1B fractions were pooled,
concentrated, and further purified on an FPLC gel-filtration
 Inhibition of PTPs by Keggin compounds
 
213column equilibrated with QA buffer.
The recombinant SHP-1 protein was overexpressed
as insoluble forms (inclusion bodies) in E. coli, thus the
protein was purified after refolding the isolated inclusion
bodies. The inclusion body proteins of SHP-1 were
isolated as described previously (Garboczi et al., 1992,
Kim et al., 1997). Refolding of the denatured SHP-1
protein was performed by a dilution method in the
presence of a glutathione redox buffer. After refolding, the
refolding mixture was concentrated with Centriprep and
Centricon to a volume of 0.5 to 1 ml. The concentrated
protein was subjected to an FPLC gel filtration column
equilibrated with QA buffer. The peak fractions were
analyzed by SDS-PAGE, and the fractions containing the
correctly folded protein were pooled and concentrated
with Centricon. Protein purity was checked by SDS-PAGE
on a 12% gel, and the protein concentration was
determined using the Bradford dye binding assay.
Phosphatase assay with pNPP 
Phosphatase activity was assayed using pNPP as a
substrate. The catalytic activities of PTP-1B, SHP-1 and
CIP were assayed at 37oC for 30 min in a reaction
mixture (0.2 ml) containing 10 mM pNPP as substrate.
The reaction was initiated by addition of each enzyme,
and quenched, after 30 min, by addition of 1 ml of 1 M
NaOH. The buffer used was QA buffer with 2 mM
dithiothreitol. The catalytic activities of the LAR and PP1
were assayed at 37oC for 30 min in a reaction mixture
(0.1 ml) containing 50 mM pNPP as substrate. The
buffers used were QA buffer with 2 mM dithiothreitol and
1 mg/ml BSA for the LAR assay, and QA buffer with 2
mM DTT and 1 mM MnCl2 for PP1 assay, respectively.
The reaction was initiated by addition of each enzyme,
and quenched, after 30 min, by addition of 0.1 ml of 2 M
NaOH. The ionic strength of each reaction mixture was
adjusted using NaCl to 0.15 M. Nonenzymatic hydrolysis
of the substrate was corrected by measuring the optical
density of the control without the addition of enzyme.
The amount of released p-nitrophenol was determined
by measuring the absorbance at 405 nm, and quantified
by comparing the values with those of control p-
nitrophenol solutions when necessary.
Determination of kinetic parameters and inhibition
constants
The catalytic activities of PTP-1B and SHP-1 were
assayed by measuring the absorbance of hydrolyzed
pNPP at 405 nm, as described above. Kinetic
parameters (Km and Vmax) were determined from a direct
fit of the velocity versus substrate concentration, to the
double reciprocal plot, using Sigmaplot 4.01 (Jandel
Scientific). Kinetic parameters were represented as
average values, determined from three independent
experiments.
The inhibition constant (Ki) for each inhibitor was
determined for PTP1B and SHP-1 as previously
described (Wang et al., 1999). Briefly, at various fixed
concentrations of each inhibitor (at least 3 or 4 different
concentrations), the initial rates at least six different
pNPP concentrations (0.2 Km to 5 Km) were measured
as described by Chen et al. (1996). The data were fitted
to the following equation to obtain the inhibition constant
of reversible competitive inhibitors.
1/v = {(Km/Vmax)(1 + [I]/Ki)}1/[S] + 1/Vmax 
The slopes obtained were replotted against inhibitor
concentrations using Sigmaplot 4.01. Ki values were
obtained from the x-intercepts of these replots. For each
compound, the inhibition constant was given as a mean
of the Ki values, obtained from three independent
experiments. 
Preparation of PTP-1B crystals 
PTP-1B crystals were grown at 4oC in a buffer containing
100 mM Hepes (pH 7.8), 200 mM magnesium acetate,
and 18%(w/v) polyethylene glycol 8000 with 10 mg/ml of
recombinant PTP-1B protein. The PTP-1B:PM complex
crystals were prepared by incubating PTP-1B crystals in a
cryosolution [100 mM Hepes, pH 7.8, 200 mM magne-
sium acetate, 18%(w/v) polyethylene glycol 8000, 25% (v/
v) glycerol, and 1 mM PM] for 2 h. To achieve uniform
distribution of the inhibitor within the crystals, relatively
small crystals (dimensions of 0.05 x 0.05 x 0.15 mm) were
used. The incubated crystal was mounted directly into a
nylon loop and flash-frozen at 100 K (Oxford Cryostream
cooling device).
Data collection and processing 
Diffraction data were collected using the DIP2030 image
plate detector on a synchrotron beam line PLS 6B, at
the Pohang Accelerator Laboratory in Korea. A
wavelength of 1.1764Å was used to collect diffraction
data with 1.5o oscillation per frame. The raw data was
processed using the HKL software package. For further
details, see Table 5.
Refinement 
In the case of the space group P3121, there is more
than one indexing possibility. Thus, a molecular re-
placement solution was determined using the CNS
software package (Brunger et al., 1998) prior to the
structure refinement. The initial model used for phase
determination was the unliganded PTP-1B structure
(Barford et al., 1994), with the WPD loop (residue 179-
187) deleted. 2Fo-Fc and Fo-Fc electron density maps,
calculated after rigid body refinement, clearly showed
the electron density for the inhibitor at the active site,
and an open conformation of the WPD loop. Three
214 Exp. Mol. Med. Vol. 34(3), 211-223, 2002cycles of refinement with the CNS, and rebuilding of the
model with the QUANTA software package (Molecular
Simulations Inc.), resulted in the final model comprising
residues 2-279, 118 ordered water molecules, and one
MoO3 molecule. All data from 20 to 2.0 Å were used for
the final round of refinement employing an isotropic bulk
solvent model (Jiang and Brunger, 1994), and it resulted
in a final crystallographic R-factor of 0.217 (Rfree=
0.239), with good geometry (Table 5).
Results
Purification and characterization of the catalytic
domains of PTP-1B and SHP-1
The protein coding regions of the catalytic domain of
PTP-1B (amino acid 1-321) (Chernoff et al., 1990) and
SHP-1 (amino acid 245-543) (Shen et al., 1991), were
cloned into an E. coli expression vector. The catalytic
domain of PTP-1B was overexpressed in E. coli as a
soluble protein, while that of SHP-1 was overexpressed
as insoluble protein aggregates (inclusion bodies). The
recombinant PTP-1B protein was purified by con-
ventional column chromatographic techniques. The re-
combinant SHP-1 protein was purified by FPLC gel-
filtration chromatography, after refolding of the isolated
inclusion bodies in a redox buffer (Garboczi et al.,
1992). The catalytic activities of the recombinant PTP-
1B and SHP-1 were measured spectroscopically using
pNPP as substrate (Chen et al., 1996). Both PTP-1B
Table 1. Percent activity of PTP-1B and SHP-1 in the presence of phosphate, phosphate analogues and their derivatives. PTP activities were measured as
described in Materials and Methods under various inhibitor concentrations. 10 mM pNPP was used as substrate.
Compounds  
Enzyme 
PTP - 1B  SHP - 1
110 150 100 200 110 150 100 200
(µM) (µM)
NaCl 102 104 106 106 102 103 108 112
Phosphate analogs
Phosphate 103 105 104 103 193 194 189 198
Thiophosphate 100 102 103 107 197 173 143 111
Vanadate 187 134 117 117 158 119 112 16
Molybdate 165 135 121 114 155 118 122 112
Tungstate 175 131 113 17 165 124 118 111
Sulfate 100 199 198 192 108 111 197 107
Thiosulfate 196 196 198 187 185 186 193 180
Metabisulfite 199 198 194 188 110 111 101 114
Nitrite 199 193 193 185 101 193 100 102
Perchlorate 101 198 100 189 188 185 183 186
Derivatives of phosphate
and phosphate analogs
Pyrophosphate 100 195 194 190 186 195 177 189
Phosphomycin 101 105 104 104 106 104 107 102
β - glycerophosphate 100 100 103 103 101 101 199 198
Vanadylsulfate 199 149 135 114 172 126 111 115
ATP 109 112 109 120 190 194 195 198
α - naphtyl acid phosphate 101 102 103 102 109 112 121 120
Phosphorus trisulfide 198 100 100 198 106 115 112 101
BpV* 178 125 111 15 155 119 111 115
Phospho molybdate (PM) 113 113 113 14 14 13 13 113
Phospho tungstate (PT) 118 113 113 12 15 14 13 112
* a peroxovanadium compound (Posner et al., 1994)
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215and SHP-1 efficiently catalyze the dephosphorylation of
pNPP under physiological conditions (pH 7.5, 0.15 M
NaCl). As reported (Tonks et al., 1988, Barrett et al.,
1999), the catalytic activities of PTP-1B and SHP-1
were modulated by DTT, a thiol containing reducing
reagent. Consistent with the previous report of PTP-1B
from human placenta (Tonks et al., 1988), the catalytic
activities of the PTPs were also modulated by EDTA.
Thus the PTP activity was measured in the presence of
2 mM dithiothreitol and 1 mM EDTA, unless otherwise
specified. The determination of kinetic parameters for
PTP-1B and SHP-1, by Lineweaver-Burk plot, resulted
in a Km value of about 4.4 mM for PTP-1B, and about
3.1 mM for SHP-1, at pH 7.5, indicating SHP-1 has a
slightly higher affinity for pNPP than PTP-1B. The Km
value of PTP-1B at pH 5.5 was slightly lower than that
at pH 7.5. The Km values are comparable to those
previously reported (Zhang and Dixon, 1994), but are
significantly higher than those values obtained from
peptide substrates containing a phosphotyrosine
residue(s) (Tonks et al., 1988, Zhang et al., 1994).
Table 2. IC50 values for the product -based inhibitors against PTP-1B and
SHP-1. IC50 values were determined at pH 7.5 by using 10 mM pNPP as
substrate.
Compounds       
Enzyme





Vandyl sulfate 57 24
BpV 23 11
Phosphomolybdate (PM) 0.15 0.12
Phosphotungstate (PT) 1.55 3.15
ND : not determined
Figure 1. Kinetic analyses of PTP-1B inhibition by phosphomolybdate and phosphotungstate. (A) The reaction rate as a function of substrate concentration
for PTP-1B under various phosphomolybdate concentrations. (B) Lineweaver-Burke plot of PTP-1B inhibition by phosphomolybdate. Total inhibitor
concentrations, bottom to top curves: 0 nM, 300 nM, 500 nM, 600 nM. (C) The reaction rate as a function of substrate concentration for PTP-1B under various
phosphotungstate concentrations. (D) Lineweaver-Burke plot of PTP-1B inhibition by phosphotungstate. Total inhibitor concentrations, bottom to top curves: 0
µM, 1 µM, 2 µM, 3 µM.
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1B and SHP-1
Using the purified PTPs, and the established enzyme
assay system, we systematically screened the pho-
sphate analogs, which have similar structure to
phosphate, and derivatives of phosphate/phosphate
analogs, that have at least one phosphate or phosphate
analogue moiety in their molecular structure, for PTP
inhibition. As shown in Table 1, we screened ten
phosphate analogs and ten derivatives of phosphate/
phosphate analogs, based on the observation that
phosphate, inhibits PTP activity with a Ki value of 4.8
mM (Zhang, 1995). Among the ten phosphate analogs
tested, vanadate, molybdate and tungstate inhibited
both PTP-1B and SHP-1 effectively, while, phosphate,
sulfate, thiosulfate, and nitrate did not significantly inhibit
the PTPs (Table 1). Interestingly, thiophosphate did not
inhibit PTP-1B up to a concentration of 200 µM, but signifi-
cantly inhibited SHP-1, suggesting that thiophosphate is
a selective inhibitor of SHP-1. Among the ten derivatives
of phosphate/phosphate analogs, a peroxovanadium
compound, bpV (Posner et al., 1994), appeared to
inhibit both PTP-1B and SHP-1 almost as effectively as
vanadate. Vanadylsulfate also appeared to inhibit the
PTPs significantly (Table 1). Remarkably, polyanionic
Keggin compounds, phosphomolybdate (PM) and phos-
photungstate (PT), appeared to inhibit both PTPs much
more strongly than vanadate, a well known, and
generally used PTP inhibitor.
To quantify the inhibitory potential of the molecules,
we determined the half-maximal inhibitory concentration
(IC50) for each inhibitor, which gave rise to a 50%
suppression of the original enzyme activity. We
observed that PM exhibited an IC50 of 0.15 µM and 0.12
µM, while PT showed an IC50 of 1.5 µM and 3.1 µM for
PTP-1B and SHP-1, respectively (Table 2). On the other
hand, the widely used PTP inhibitor, vanadate, gave rise
to an IC50 of 33 µM and 13 µM for PTP-1B and SHP-1,
respectively. Molybdate, tungstate, and bpV, exhibited
similar inhibitory effect to vanadate, with an IC50 of
Figure 2. Kinetic analyses of SHP-1 inhibition by phosphomolybdate and phosphotungstate. (A) The reaction rate as a function of substrate concentration for
SHP-1 under various phosphomolybdate concentrations. (B) Lineweaver-Burke plot of SHP-1 inhibition by phosphomolybdate. Total inhibitor concentrations,
bottom to top curves: 0 nM, 50 nM, 100 nM, 200 nM. (C) The reaction rate as a function of substrate concentration for SHP-1 under various phosphotungstate
concentrations. (D) Lineweaver-Burke plot of SHP-1 inhibition by phosphotungstate. Total inhibitor concentrations, bottom to top curves: 0 µM, 1 µM, 2 µM,
5 µM. 
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21720~30 µM for PTP-1B and 10~20 µM for SHP-1.
Thiophosphate selectively inhibited SHP-1 only, with an
IC50 of ~90 µM. These results clearly indicate that PM
and PT are the most potent inhibitors among various
product-based PTP inhibitors, and that thiophosphate is
a specific inhibitor for SHP-1.
PM and PT are competitive, reversible inhibitors of
PTP-1B and SHP-1
Next, we determined the Ki values for the product-based
inhibitors, against PTP-1B and SHP-1, using
Lineweaver-Burk plots (Figures 1 and 2). The inhibition
kinetics of PM and PT appeared to be those of
competitive inhibitors, with Ki of 0.16 and 1.2 µM against
PTP-1B, and with Ki of 0.06 and 0.79 µM against SHP-
1 at pH 7.5, respectively (Table 3). Inhibition of PTP
activity, by PM and PT, was almost completely reversed
when the reaction mixture was diluted or dialyzed, and
the inhibition was not affected, regardless of the
preincubation between the enzyme and inhibitors (data
not shown), indicating that PM and PT are reversible
inhibitors. The patterns of inhibition by vanadate,
molybdate, and tungstate all correspond to that
expected for competitive inhibition, with Ki of 5.6, 3.7
and 17.7 µM, for PTP-1B and 9.3, 1.3, and 4.5 µM for
SHP-1 at pH 7.5, respectively (Table 3). At neutral pH
7.5, the observed affinity, of PM and PT, for PTP-1B (Ki
=0.16 and 1.2 µM, respectively) is about 40- and 5-fold
higher than that of vanadate (Ki=5.6 µM). The
observed affinity of PM and PT for SHP-1 is also about
150- and 10-fold higher than that of vanadate. PM and
PT potently inhibited PTPs when the reactions were
assayed using phosphotyrosine containing peptides as
substrate (data not shown).
Ki values of PM and PT against PTP-1B appeared to
be dependent on pH, with about a 10-fold lower potency
at pH 5.5 than at pH 7.5 (Table 3). Even at pH 5.5, the
optimal pH of PTP-1B, the observed affinity of PM and
PT for PTP-1B is about 300- and 40-fold higher than that
of the vanadate (Table 3). Interestingly, unlike the
product-based PTP inhibitors such as vanadate, PM,
and PT, small organic molecule inhibitors such as OBA
and its derivatives, are known to inhibit PTPs more
effectively at pH 5.5 than at pH 7.5 (Andersen et al.,
2000, Iversen et al., 2000), and F2Pmp, containing
phosphotyrosyl mimetic inhibitors, appear to potently
inhibit PTPs independent of pHs (Chen et al., 1995).
Effect of EDTA on the PTP-1B inhibition by PM and PT  
EDTA is known to chelate vanadium compounds, and
thus significantly decreases their inhibition potencies
(Huyer et al., 1998). To investigate the effect of EDTA on
the PTP-1B inhibition by PM and PT, PTP inhibition
assays were performed in the absence of EDTA. PTP-
1B prepared in the absence of EDTA was used for this
purpose. As expected, IC50 values of vanadate, mo-
lybdate and tungstate were significantly decreased in
the absence of EDTA (Table 4). However, IC50 values of
PM and PT were less affected, suggesting that EDTA
chelates less weakly with these molecules than with the
vanadate. Consequently, inhibition competencies of va-
nadate and PM appeared to be similar in the absence
of EDTA.
 
Table 3. Ki values for the product based inhibitors against PTP-1B and SHP-1 at pH 7.5 and pH 5.5. Ki  values were determined as indicated in Materials and
Methods.
Compoud                    
 Enzyme
PTP-1B (pH 7.5) PTP-1B (pH 5.5) SHP-1 (pH 7.5)
(µM) (µM) (µM)
Vanadate 5.6 ± 0.82 409.5 ± 82.1 9.3 ± 0.92
BpV 5.2 ± 0.92 ND 16.7 ± 3.12
Molybdate 3.7 ± 0.62 ND 1.3 ± 0.22
Phosphomolybdate 0.16 ± 0.02 1.41 ± 0.55 0.06 ± 0.01
Tungstate 17.7 ± 0.82 ND 4.5 ± 0.72
Phosphotungstate 1.2 ± 0.22 10.5 ± 0.22 0.79 ± 0.02
ND : not determined
Table 4. Half-maximal inhibitory concentration (IC50) values of the product
based inhibitors for PTP-1B in the absence of EDTA









ND : not determined
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We investigated whether PM and PT can inhibit other
phosphatase families, such as receptor tyrosine
phosphatase (LAR), Ser/Thr phosphatase (PP1), and
alkaline phosphatase (CIP), as well as cytosolic PTPs
such as PTP-1B and SHP-1. As shown in Figure 3,
PM and PT effectively inhibited LAR with IC50 values
less than 5 µM, though less in the cases of PTP-1B or
SHP-1 (Table 2). The catalytic activity of CIP was not
affected by PM and PT at all, while that of PP1 was
slightly inhibited with IC50 of about 70 µM. These
results indicate PM and PT to be very potent PTP
inhibitors, but they are not strong inhibitors against
alkaline phos-phatase and Ser/Thr phosphatase.
Inhibition mechanism of PTP-1B by PM
To understand how the Keggin compounds inhibit PTPs,
we determined the crystal structure of PTP-1B com-
plexed with PM, at 2.0 Å resolution, using the molecular
replacement method. The initial Fo-Fc map, calculated
after rigid body refinement of the PTP-1B structure
(Barford, et al., 1994), showed a strong electron density
(>6σ) near the Sγ atom of the Cys215. The 2Fo-Fc omit
map, calculated after simulated annealing refinement,
clearly exhibited a trigonal, pyramid-shaped electron
density at the active site (Figure 4A). The electron
density resembles that of the MoO3 monomer calculated
by density functional theory using the Gaussian 94
program, and predicted by IR absorption analysis.
Therefore, it is highly likely the well-defined electron
density at the active site is that of MoO3 which must
originate from the PM. MoO3 in the active pocket has a
trigonal pyramid structure with a M-O bond length of
1.74 Å and O-M-O bond angle of 109.6o. This result
Figure 3. Concentration-dependent inhibition of PTP-1B, SHP-1, LAR, CIP,
and PP1 by phosphomolybdate (upper panel) and phosphotungstate (lower
panel). PTP-1B activity is designated by open circles () as a function of
inhibitor concentration; SHP-1 activity is by closed circles (); LAR activity
is by closed triangles ( ); PP1 activity is by closed squares ( ); and CIP
activity is by open triangles ()
Figure 4. The stereo view of a 2Fo-Fc omit map at the active site. Contour levels are 1.3 and 6, respectively. The side chain of Gln262, inhibitor molecule
(MoO3), and the coordinated water molecules (WAT1 and WAT2) have been omitted from the model during the simulated annealing refinement. The three
oxygen atoms of MoO3 interact with the main-chain nitrogen and side chain of Arg221 in the PTP signaling motif, forming tight hydrogen bonds. The amide
side chain of Gln262 forms a hydrogen bond with one of coordinated water molecule (WAT1).
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219suggests that MoO3 derived from PM, by hydrolysis,
binds at the active site and consequently inhibits PTP-
1B. In support of the crystallographic finding, we
observed the molybdenum oxides (MoO3, MoO2 and
MoO2Cl2) inhibited PTP-1B with IC50 in the range 5-15
µM (data not shown).
The three oxygen atoms of MoO3 form eight tight
hydrogen bonds to the main-chain NH group of the PTP
signature motif (residue 215-221), and the side chain of
Arg221, and the molybdenum atom is located adjacent
to the nucleophilic sulfur of the Cys215. The side chain
of Arg221 adopts its optimum conformation for
electrostatic/hydrogen bonding interactions with the
bound MoO3 (Figure 4). Interestingly, two water
molecules (WAT1 and WAT2) are found in close
proximity to the Mo atom of MoO3 (Figure 5). Thus the
molybdenum atom of the inhibitor is coordinated with six
ligands: three oxo-ligands from MoO3, two apical water
molecules and a S atom of the catalytic cysteine residue
(Figure 5). The Mo-WAT1 and Mo-WAT2 distances are
3.31 Å and 3.34 Å, respectively, and the Mo-Sγ distance
is 3.12Å. Interestingly, the coordinated WAT1 molecule
attracts the side chain of Gln262 into the active site by
forming a hydrogen bond with the N2-WAT1 distance of
2.91Å (Figure 4; Figure 6C), while the Gln262 is away
from the active site in the unliganded PTP-1B structure
(Barford et al., 1994). This movement of the Gln261 side
chain has also been observed in the tungstate, and
vanadate, complexed PTP-1B structures (Figure 6A and
B) (Barford et al., 1994, Pannifer et al., 1998). 
Discussion
Previous studies have shown that PTPs can be inhibited
by phosphate, the end product of PTP catalyzed
reaction, with a Ki value in the milimolar range (Zhang,
1995), and by phosphate analogs such as vanadate
with a Ki value in the micromolar range (Swarup et al.,
1982, Huyer et al., 1997). In this study, using the purified
recombinant PTPs and pNPP as substrate, we have
systematically investigated the inhibitory potentials of
diverse compounds that have at least one phosphate, or
phosphate analog moiety, in their molecular structures.
As expected, phosphate analogs such as vanadate,
molybdate, and tungstate appear to effectively inhibit
both PTP-1B and SHP-1, with Ki values in micromolar
ranges under the assay conditions used. Interestingly,
thiophosphate appears to selectively inhibit SHP-1, and
derivatives of vanadate such as peroxovanadyl
compounds (Posner et al., 1994) and vanadylsulfate
also appears to effectively inhibit both PTP-1B and
SHP-1. Most importantly, our kinetic data indicate that
phosphomolybdate (PM) and phos-photungstate (PT)
work as potent, competitive, and reversible inhibitors
against PTP-1B and SHP-1. PM and PT appear to
strongly inhibit other PTPs such as LAR, but they
weakly inhibit Ser/Thr phosphatase, but do not inhibit
alkaline phosphatase at all. Unexpectedly, the crystal
structure of PTP-1B complexed with PM reveals that
MoO3, derived from PM by hydrolysis, binds at the
active site. The molybdenum atom of the inhibitor is six-
coordinated with three oxo-ligands from MoO3, two
apical water molecules and a S atom from the catalytic
cysteine residue.
Our kinetic analyses show that PM and PT reversibly
inhibit PTPs, with Ki values in the nanomolar range, in
the presence of 1 mM EDTA. These Ki values are about
50 times lower than the Ki value of vanadate (Table 3).
Most of the potent PTP inhibitors so far reported display
Ki values in the hundred-nanomolar range. For
example, the Ki value of vanadate against PTP-1B has
been reported to be 0.38 µM in the absence of EDTA
(Huyer et al., 1997). The lowest Ki value of the F2Pmp
containing peptide, against rat PTP1, has been reported
to be 0.12 µM at pH 7.0 (Chen et al., 1995). Recently,
Iverson et al. (2000) reported the Ki value of an OBA
derivative, against PTP-1B, as 0.29 µM at pH 5.1.
Although it is difficult to directly compare the inhibition
potential of those inhibitors, mainly due to the
differences in the inhibition assay, PM and PT seem to
be one of the most potent PTP inhibitors so far
developed judging from the reported Ki values. It is clear
that PM and PT inhibit PTPs much more strongly than
vanadate/molybdate/tungstate in the presence of EDTA.
Previous studies have shown that EDTA chelates
vanadate, and consequently decreases the inhibition
potential of the molecule. Our data also demonstrate
that vanadate inhibits PTP-1B much more strongly in
the absence of EDTA (Table 4) than in its presence
(Table 2). However, the inhibition potential of PM and PT
does not appear to be significantly affected by EDTA
(Table 2 and Table 4). As a result, the inhibition potential
of PM and PT appears to be similar to that of vanadate
in the presence of EDTA.  
We have shown that PM and PT are general inhibitors
of PTPs (Figure 3). PM and PT potently inhibit
cytoplasmic PTPs such as PTP-1B and SHP-1, and
receptor-like PTPs such as LAR. However, PM and PT
appear to be poor inhibitors of Ser/Thr phosphatase
such as PP1. Particularly, PM and PT do not inhibit
alkaline phosphatase, even at millimolar concentrations.
Although PM and PT, as general and potent PTP
inhibitors, lack specificity, they could be useful tools for
knocking out all the PTP functions in in vitro, as well as
in ex vivo, or in vivo studies. In particular, PM and PT
would be more useful than vanadate for in vitro studies,
since their inhibition potential is not significantly affected
by EDTA.
The catalytic PTP domains contain a distinct sequence
motif of 11 amino acid residues, I/VHCXXGXXRS/TG, at
the active site. The Cys residue is critical in the catalytic
220 Exp. Mol. Med. Vol. 34(3), 211-223, 2002activity of PTPs functioning as a nucleophile that form a
thiol-phosphate intermediate during catalysis (Guan and
Dixon, 1991, Zhou et al., 1994). The Cys residue is
easily inactivated by sulfhydryl oxidizing and alkylating
agents (Zhang and Dixon, 1993). The crystal structure of
PTP-1B, complexed with PM, reveals that MoO3 binds at
the active site forming a thiol-molybdenum ester linkage
between the Cys residue and the central molybdenum
atom. Polyanionic Keggin compounds, PM (12MoO3·
H3PO4) and PT (12WO3·H3PO4), contain twelve MoO3
or WO3 moieties, and one PO4 moiety in the molecular
structure. Those Keggin compounds are known to
hydrolyze in aqueous solution to an equilibrium con-
centration of various components. Therefore, it is highly
likely that MoO3, derived from PM by hydrolysis, actually
inhibits PTPs, although it is not yet known whether the
Cys residue at the active site functions as a nucleophile
to hydrolyze PM. Interestingly, we observed that
molybdenum oxides (MoO3, MoO3 and MoO2Cl2) inhibited
PTPs. However, the inhibition potential of MoO3 appeared
to be lower than PM, considering PM contains 12 MoO3
units.
Vanadate is a phosphate analog, since it can adopt a
similar structure to inorganic phosphate. The three
dimensional structure of the PTP-1B complexed with
vanadate reveals that the vanadate molecule occupies
the active site forming a thiol-vanadyl ester linkage
between the central vanadium atom and the Sã atom of
Cys215, which is colinear with the apical oxygen-
vanadium bond (Pannifer et al., 1998). Thus the
vanadate in the active site forms a pentavalent trigonal
bipyramidal structure (Figure 6A). The structure of
vanadate, complexed with PTP-1B, is very similar to the
transition state of the cysteinyl-phosphate intermediate
when being attacked by a nucleophilic water, forming a
pentavalent phosphorus intermediate (Denu et al.,
1996). The apical oxygen of the vanadate is hydrogen
bonded with amide side chains of Gln262. The side
chain of Asp181 also interacts with the apical oxygen,
causing the closed conformation of the WPD loop
(residues 179-187). Tungstate has also been shown to
bind at the active site of PTP (Barford et al., 1994),
forming a distorted trigonal bipyramidal structure.
However, in the tungstate-complexed PTP-1B, the side
chain of Gln262 does not bind tightly to the tungstate.
The shortest length, between the apical oxygen of
tungstate and the amide side chain of Gln262, is just
3.8Å (Figure 6B). Similar to the case of vanadate or
tungstate, MoO3 binds to the active site of the PTP-1B.
However, the binding mode and conformation of MoO3,
complexed with PTP-1B, appear to be quite distinct
(Figure 6C). Most importantly, MoO3 bound to the active
site exhibits an extremely distorted hexavalent octahedral
geometry, with three oxoligands, and three additional
ligands from a sulfur atom of Cys215 and from two
oxygen atoms of water molecules (Figure 5). The three
oxo ligands are hydrogen bonded with the amide side
chain of Arg221 and the amide backbone of Ser216,
Ala217, Gly218, Ile219 and Gly220 (Figure 4). One of
the water ligands (WAT1) is hydrogen bonded more
tightly with the amide side chain of Gln262 than in the
case of vanadate or tungstate (Figure 6C). 
Figure 5. MoO3 complexed with PTP-1B, forms an extremely distorted
hexavalent octahedral structure. Six-coordination is achieved by three oxo-
ligands, two water molecules, and the Sγ atom of Cys215. 
Figure 6. Comparison of the inhibitor binding sites. (A) A stereo view of PTP-
1B:Vanadate complex. Vanadium atom and Sγ of Cys215 form a covalent
bond colinear with the apical oxygen-vanadium bond. The apical oxygen is
hydrogen bonded with the side chains of Gln262 and Asp181. Thus the
WPD loop (residues 179-187) is closed in this structure. (B) A stereo view
of PTP-1B:tungstate complex. The tungsten atom forms a covalent bond
with the Sγ of Cys215, and the apical oxygen is hydrogen bonded with the
side chain of Gln262. (C) A stereo view of  PTP-1B:MoO3 complex.
Molybdenum atom forms a covalent bond with the Sγ of Cys215, and an
apical water molecule (WAT1) forms a tight hydrogen bond with the side
chain of Gln262. Note that tungstate and MoO3 do not induce the closure of
the WPD loop.
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221Unlike the case of vanadate, MoO3 does not form a
hydrogen bond with Asp181. As a result, the PTP-1B
structure in complex with MoO3 adopts an open
conformation of the WPD loop (residues 179-187),
which is characteristic of the unliganded state of PTP1B
(Barford et al., 1994). The open conformation of the
WPD loop was also observed in the PTP1B-tungstate
(Barford et al., 1994) and PTP1B-fluoromalonyl tyrosine
(FOMT)-based cyclic peptide complex structures
(Groves et al., 1998). It has been observed from the
structure of PTP-1B complexed with a FOMT-based
cyclic peptide, which has a Ki value of 0.17 mM, the
closure of the WPD loop is not essential for the high
inhibitory potential of PTP inhibitor. If the present
structure PTP-1B:MoO3 complex would adopt the
closed form of the WPD loop, Asp181 could improve the
MoO3 binding affinity by hydrogen bonding to the highly
ordered WAT2 molecule. However, the fact the binding
of MoO3 does not induces closure of the WPD loop, the
inhibitory potential is not expected to be improved much
by the simple closure of the WPD loop, without any
additional interactions such as aromatic-aromatic
interaction between the side chain of Phe182 and an
aromatic moiety of an inhibitor.
Many attempts have already been made to develop
vanadium derivatives with high potency, high selectivity,
and low toxicity. For example, vanadylsulfate and
vanadyl[bis(maltalato)oxovanadium (IV)] have been
synthesized, and shown to inhibit PTPs with similar
potency to vanadate (Yuen et al., 1993). A variety of
vanadate complexes including bismaltooxovanadates,
and peroxovanadates with different ancillary ligands,
have been synthesized. Some of these have been
shown to increase the level of insulin receptor
phosphorylation (Posner et al., 1994, Poucheret et al.,
1998). Recently, a complex of vanadate with di-
methylhydroxylamine has been synthesized and shown
to reversibly inhibit PTP-1B and LAR, with a Ki in the
micromolar range. Similar approaches would be worth
trying with MoO3 in an attempt to come up with more
selective and cellularly active, but less toxic, PTP
inhibitors. Highly selective and potent PTP inhibitors
could be used as essential tools in revealing the
biological function of specific PTPs, as well as having
high potential as therapeutic agents.
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